Literature DB >> 30699866

Empirically-derived response trajectories of intensive residential treatment in obsessive-compulsive disorder: A growth mixture modeling approach.

Martha J Falkenstein1, Jacob A Nota2, Jason W Krompinger3, Meghan Schreck4, Lauryn E Garner5, Sriramya Potluri6, Nathaniel Van Kirk7, Gabriella Ponzini8, Eric Tifft9, Brian P Brennan10, Brittany Mathes11, Jordan Cattie12, Jesse M Crosby13, Jason A Elias14.   

Abstract

BACKGROUND: This study investigated distinct trajectories of treatment response in a naturalistic intensive/residential treatment (IRT) program for adults with severe obsessive-compulsive disorder (OCD). We hypothesized that: (1) distinct trajectories would emerge and (2) demographic variables, psychiatric comorbidity, OCD symptom subtype, level of insight, previous exposure and response prevention (ERP) treatment, and quality of life, would differentially predict assignment to these trajectories.
METHODS: Participants included 305 individuals with primary OCD admitted for IRT.
RESULTS: Two trajectories emerged over the course of the first eight weeks of treatment, with the vast majority of participants demonstrating treatment response. The first trajectory (96%, n = 292) showed a negative, linear treatment response (a.k.a. "linear responders") and more severe OCD symptoms at admission. The second trajectory (4%, n = 13) had less severe OCD symptoms at admission and did not exhibit a significant overall change in symptoms over the course of treatment. More specifically, this second trajectory or "u-shaped responders" show a non-significant linear response through week four of treatment, followed by slightly increased symptoms in week five. Assignment to these classes was not differentially predicted by hypothesized predictor variables. LIMITATIONS: Our final model had inconsistent fit indices and small class prevalance of the u-shaped responder group; therefore, model selection was based on both fit indices and substantive meaning.
CONCLUSIONS: This study emprically derived two distinct trajectories of OCD symptom severity over the course of IRT. These findings have the potential to refine IRT for patients with severe OCD, and to potentially guide future investigation into the optimal delivery of ERP treatment for OCD generally.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Obsessive-compulsive disorder; Treatment outcome

Mesh:

Year:  2018        PMID: 30699866     DOI: 10.1016/j.jad.2018.11.075

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Long-term Outcomes of Intensive Inpatient Care for Severe, Resistant Obsessive-Compulsive Disorder: Résultats à long terme de soins intensifs à des patients hospitalisés pour un trouble obsessionnel-compulsif grave et résistant.

Authors:  Srinivas Balachander; Aakash Bajaj; Nandita Hazari; Ajay Kumar; Nitin Anand; M Manjula; Paulomi M Sudhir; Anish V Cherian; Janardhanan C Narayanaswamy; T S Jaisoorya; Suresh Bada Math; Thennarasu Kandavel; Shyam Sundar Arumugham; Y C Janardhan Reddy
Journal:  Can J Psychiatry       Date:  2020-05-26       Impact factor: 4.356

2.  Predictors of Intensive Treatment in Patients With Obsessive-Compulsive Disorder.

Authors:  Johanna A M du Mortier; Karin C P Remmerswaal; Neeltje M Batelaan; Henny A D Visser; Jos W R Twisk; Patricia van Oppen; Anton J L M van Balkom
Journal:  Front Psychiatry       Date:  2021-04-12       Impact factor: 4.157

3.  Latent class growth modelling for the evaluation of intervention outcomes: example from a physical activity intervention.

Authors:  Anna-Maria Lampousi; Jette Möller; Yajun Liang; Daniel Berglind; Yvonne Forsell
Journal:  J Behav Med       Date:  2021-03-25

Review 4.  Identifying typical trajectories in longitudinal data: modelling strategies and interpretations.

Authors:  Moritz Herle; Nadia Micali; Mohamed Abdulkadir; Ruth Loos; Rachel Bryant-Waugh; Christopher Hübel; Cynthia M Bulik; Bianca L De Stavola
Journal:  Eur J Epidemiol       Date:  2020-03-05       Impact factor: 12.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.